ARMP

Company Overview — What Does Armata Pharmaceuticals, Inc. Do?

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California. Armata Pharmaceuticals, Inc. (ARMP) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Brian C. Varnum and employs approximately 70 people, headquartered in MARINA DEL REY, California. With a market capitalization of $387M, ARMP is one of the notable companies in the Healthcare sector.

Armata Pharmaceuticals, Inc. (ARMP) Stock Rating — Reduce (April 2026)

As of April 2026, Armata Pharmaceuticals, Inc. receives a Reduce rating with a composite score of 35.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ARMP ranks #2,499 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Armata Pharmaceuticals, Inc. ranks #320 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ARMP Stock Price and 52-Week Range

Armata Pharmaceuticals, Inc. (ARMP) currently trades at $11.12. The stock lost $0.41 (3.6%) in the most recent trading session. The 52-week high for ARMP is $16.34, which means the stock is currently trading -31.9% from its annual peak. The 52-week low is $0.90, putting the stock 1138.2% above its annual trough. Recent trading volume was 18K shares, suggesting relatively thin trading activity.

Is ARMP Overvalued or Undervalued? — Valuation Analysis

Armata Pharmaceuticals, Inc. (ARMP) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 64.45x, compared to 1.66x for the average Healthcare stock.

At current multiples, Armata Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Armata Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Armata Pharmaceuticals, Inc. (ARMP) earns a quality factor score of 17/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -71.5% versus the sector average of -33.1%.

On a margin basis, Armata Pharmaceuticals, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -745.7% (sector: -66.1%). Net profit margin stands at -1141.8%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ARMP Debt, Balance Sheet, and Financial Health

Balance sheet data for ARMP is evaluated through our stability factor. The current ratio is 1.19x, suggesting adequate working capital coverage. Total debt on the balance sheet is $146M. Cash and equivalents stand at $15M.

ARMP has a beta of 0.31, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Armata Pharmaceuticals, Inc. is 34/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Armata Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Armata Pharmaceuticals, Inc. reported revenue of $7M and earnings per share (EPS) of $-4.80. Net income for the quarter was $-55M. Gross margin was 100.0%. Operating income came in at $-33M.

In FY 2025, Armata Pharmaceuticals, Inc. reported revenue of $5M and earnings per share (EPS) of $-4.80. Net income for the quarter was $-174M. Revenue grew -5.2% year-over-year compared to FY 2024. Operating income came in at $-37M.

In Q3 2025, Armata Pharmaceuticals, Inc. reported revenue of $1M and earnings per share (EPS) of $-0.74. Net income for the quarter was $-27M. Revenue grew -61.0% year-over-year compared to Q3 2024. Operating income came in at $-8M.

In Q2 2025, Armata Pharmaceuticals, Inc. reported revenue of $2M and earnings per share (EPS) of $-0.45. Net income for the quarter was $-16M. Operating income came in at $-7M.

Over the past 8 quarters, Armata Pharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $7M. Investors analyzing ARMP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ARMP Dividend Yield and Income Analysis

Armata Pharmaceuticals, Inc. (ARMP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ARMP Momentum and Technical Analysis Profile

Armata Pharmaceuticals, Inc. (ARMP) has a momentum factor score of 79/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 14/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ARMP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Armata Pharmaceuticals, Inc. (ARMP) ranks #320 out of 838 stocks based on the Blank Capital composite score. This places ARMP in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ARMP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ARMP vs S&P 500 (SPY) comparison to assess how Armata Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

ARMP Next Earnings Date

No upcoming earnings date has been announced for Armata Pharmaceuticals, Inc. (ARMP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ARMP? — Investment Thesis Summary

The quantitative profile for Armata Pharmaceuticals, Inc. suggests caution. The quality score of 17/100 flags below-average profitability. The value score of 22/100 indicates premium valuation. Price momentum is positive at 79/100, suggesting the trend favors buyers. High volatility (stability score 34/100) increases portfolio risk.

In summary, Armata Pharmaceuticals, Inc. (ARMP) earns a Reduce rating with a composite score of 35.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ARMP stock.

Related Resources for ARMP Investors

Explore more research and tools: ARMP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ARMP head-to-head with peers: ARMP vs AZN, ARMP vs SLGL, ARMP vs VMD.